Medizinportal Arztsuche Apothekensuche KliniksucheHealth Provider Directory - Health in Germany - english-language-version
Home DocSearch ClinicSearch HealthSites

News

2011-03-04:
/C O R R E C T I O N - - Bristol - Myers Squibb and AstraZeneca/
Paris and London ( PRN/ots ) - In the news release, "ONGLYZA( R ) Becomes the First DPP - 4 Inhibitor Available for Use in Europe" issued on 4 Mar 2011 08:00 GMT, by Bristol - Myers Squibb and AstraZeneca NYSE:AZN over PR Newswire, we would like (...)
2005-10-10:
World Mental Health Day 2005 Examines the Close Link Between Mental and Physical Health Across the Life Span
Washington D.c. ( PRN/ots ) - - Dr Benedetto Saraceno of WHO Will Keynote a Symposium to Mark 2005 WMHD in Washington D.C. The 13th World Mental Health Day ( WMHD ) will be celebrated today in many countries and this year examines the close relationship between (...)
2009-07-20:
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA( TM ) in Systemic Lupus Erythematosus
Rockville, Maryland and London ( PRN/ots ) - - BENLYSTA ( belimumab ) met its primary efficacy endpoint by achieving a statistically significant improvement in patient response rate versus placebo in BLISS - 52 - - First drug for lupus to reach this advanced stage of clinical development and (...)
2007-03-08:
Ansell Healthcare Welcomes Commission's Initiative to Reduce Occupational Accidents in the EU by 25%
Brussels ( PRN/ots ) - Ansell Healthcare, a world leader in barrier protection, welcomes the European Commission's recently announced strategy to reduce occupational accidents and diseases in the European Union by 25 Prozent by 2012. Ansell Healthcare, a producer of both medical and industrial gloves, claims that (...)
2005-02-17:
Aplidin( R ) Commences Phase II Clinical Trials in Prostate and Bladder Cancers
Madrid, Spain ( PRN/ots ) - PharmaMar announces that its second most advanced marine - derived anti - tumour agent, Aplidin( R ), has commenced Phase II clinical trials in both prostate and bladder cancers. Phase II trial in Prostate Cancer This is the first trial of Aplidin in (...)
2008-01-05:
cbm Expanding its Mandate
Toronto ( PRN/ots ) - - President of cbm, Prof. Allen Foster Announces That cbm Has Expanded its Areas of Work to Include All Persons With Disability, Not Just Persons With Visual Loss. For the past 100 years, cbm previously known as Christoffel Blinden Mission, (...)
2008-06-26:
Bowel Cancer Patients Live Longer Taking Xeloda
Barcelona, Spain ( PRN/ots ) - - Analysis Confirms That Oral Xeloda is Superior to IV 5 - FU - Not for US Media A pre - planned multivariate analysis of the five - year follow - up data shows that patients receiving chemotherapy after - surgery to treat colon (...)
2008-06-30:
Honda to Conduct Collaborative Testing of its Walking Assist Device
Tokyo ( PRN/ots ) - Honda Motor Co., Ltd. will begin collaborative testing of its experimental walking assist device as from July 1, 2008, with Shinseikai Medical Group, Kasumigaseki - Minami Hospital ( Kawagoe, Saitama prefecture ). The device was created to support walking by the elderly and other (...)
2008-12-09:
MabThera Maintenance Therapy Helps Non - Hodgkin's Lymphoma Patients Live for Years Longer Without Their Disease Progressing
Basel, Switzerland ( PRN/ots ) - - For non - US and non - UK Media Only - Long - term Results From a Phase III Study Highlight the Beneficial Role of MabThera in Patients With Recurrent or Resistant Disease Data presented at the 50th Annual Meeting of (...)
2005-12-01:
Quintiles Extends Asia Operations With Opening of Vietnam Office
Research Triangle Park, North Carolina ( PRN/ots ) - - Now has clinical development offices in eight Asia countries Quintiles Transnational Corp. today announced the extension of its Asia operations with the opening of an office in Hanoi, Vietnam. "Vietnam is an increasingly (...)
2007-05-25:
MIRCERA Receives Positive Opinion in Europe for the Treatment of Anaemia due to Chronic Kidney Disease
Basel, Switzerland ( PRN/ots ) - Roche announced today that it has received a positive opinion from the European Committee for Medicinal Products for Human Use ( CHMP ) recommending a marketing authorisation be granted for MIRCERA for the treatment of anaemia associated with chronic kidney disease. MIRCERA (...)
2005-09-15:
Aplidin( R ) Commences Combination Trials
Madrid ( PRN/ots ) - - Further Steps in the Development of Aplidin( R ) in Melanoma in First Line Therapy PharmaMar announces the initiation of a programme of combination studies with Aplidin( R ) ( plitidepsin ), PharmaMar's novel marine - derived anti - tumour agent, originally isolated from the tunicate Aplidium albicans. (...)
2007-01-18:
GlaxoSmithKline Initiates Head - to - Head Study of Cervical Cancer Vaccines
Philadelphia, Pennsylvania ( PRN/ots ) - - Study to Compare Immunogencity of GSK's Cervical Cancer Candidate Vaccine, CERVARIX( R ), to Merck's Gardasil( R ) GlaxoSmithKline ( NYSE: GSK ) announced today the initiation of the first study of its kind designed to compare the immunogenicity of its cervical cancer candidate (...)
2009-10-01:
Takeda to Establish Four Sales and Marketing Subsidiaries to Expand its Operations in Mexico, Turkey and Five Other Countries in Europe
Osaka, Japan ( PRN/ots ) - Takeda Pharmaceutical Company Limited ( Osaka, Japan, "Takeda" ) announced today it will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries - Takeda Pharmaceuticals Mexico, S.A. de C.V., Takeda Pharmaceuticals Trade, LLP ( Turkey ), Takeda (...)
2006-08-09:
Archbishop Desmond Tutu Launches 100,000 Cataract Operations in 100 days
Cape Town, South Africa ( PRN/ots ) - "We can really do something to change the world," says Archbishop Desmond Tutu. "I think not being able to see is one of the most debilitating disabilities in our world today," Archbishop Tutu said at the launching of (...)
2007-07-25:
New SPIRIVA( R ) Respimat( R ) Inhaler Completes European Approval Process for COPD
Ingelheim, Germany ( PRN/ots ) - - Patients to Benefit From Easy - to - Use Inhaler With Enhanced Drug Delivery Boehringer Ingelheim and Pfizer today announced successful completion of the approval process for authorisation to market SPIRIVA( R ) Respimat( R ) in the European Union for people with chronic obstructive (...)
2008-09-26:
Kelly Osbourne and International Health Groups Call for Improved Education on Choices and Usage of Contraception
London ( PRN/ots ) - - World Contraception Day 2008 Highlights Scale and Impact of Unplanned Pregnancy Today, international sexual and reproductive health experts and successful recording artist and media personality Kelly Osbourne, call for more action to address the burgeoning problem of unplanned pregnancies and (...)
2008-11-10:
First Study in Real - Life Setting Confirms That Once - Monthly Mircera Keeps Haemoglobin Levels Within a Tight Range
Basel, Switzerland, November 10 ( PRN/ots ) - - Results Demonstrate Effective and Simplified Approach to Anaemia Management in Chronic Kidney Disease Patients on Dialysis Interim study results from 90 renal centres in Germany confirm for the first time that in a real - life (...)
2008-09-18:
Agendia's MammaPrint( R ) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
HUNTINGTON BEACH, California and AMSTERDAM, Netherlands, September 18 ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, today announced that its signature breast cancer tumor recurrence test, MammaPrint( R ), has been included in the updated 2008 guidelines of The Dutch Institute for Healthcare (...)
2010-03-31:
Cellvax Expands its Preclinical Service Offers by Moving to a New Laboratory Facility With an Access to Large Animals and a Number of New Technical Plat - Forms
Paris, March 31, 2010 ( PRN/ots ) - Cellvax is a French service company which provides complete in vitro & in vivo preclinical innovating services allowing to accelerate the drug development process for unmet needs related with severe human diseases, mainly in oncology field. Cellvax was (...)
2008-11-11:
Dronedarone ( Multaq( R ) ) Reduced the Incidence and Duration of Hospitalization in Patients With Atrial Fibrillation
New Orleans, Louisiana, November 11 ( PRN/ots ) - - New Post - Hoc Analysis From Athena Study Showed That Multaq( R ) on Top of Standard Therapy Significantly Decreased the Total Number of Hospital Days by 28 Prozent in Patients With Atrial Fibrillation or Flutter NEW ORLEANS, Louisiana, November (...)
2004-08-03:
ProMetic, The American Red Cross and Macopharma to Market the First Product for the Selective Adsorption of Prions out From Blood and Blood Derivatives
Cambridge, England, Montreal, Canada. Washington D.c. and Lille, France ( PRN/ots ) - - Initial European Roll out Planned for 2005 - Strategic Alliance to Include Development of Filters for Viruses - MacoPharma to Market and Distribute the Products - Financial Arrangement Based on Revenue Sharing (...)
2009-11-18:
Boehringer Ingelheim and GlaxoSmithKline Back EFA's Call for Urgent Improvements in Care for People With Lung Disease This World COPD Day
Brussels, Ingelheim, Germany and London, November 18 ( PRN/ots ) - Boehringer Ingelheim and GSK, companies with a strong heritage in COPD ( chronic obstructive pulmonary disease ) and a commitment to improved patient care, have today announced their support of The European Federation of Allergy and (...)
2005-10-07:
The Lancet Publishes Groundbreaking Proactive Study Showing Type - 2 Diabetes Treatment Significantly Reduces Risk of Non - Fatal Heart Attacks, Strokes and Deaths
London ( PRN/ots ) - - Takeda's ACTOS( R ) ( pioglitazone HCl ) on Top of Standard Treatment Demonstrates Significant Cardiovascular Benefits A study published in The Lancet today shows that Takeda's ACTOS( R ) ( pioglitazone HCl ), an oral glucose lowering medication, significantly reduces the combined risk of non - fatal (...)
2004-12-22:
Abbott Announces Regulatory Submissions for Use of HUMIRA( R ) ( adalimumab ) as First - Line Treatment for Rheumatoid Arthritis
Abbott Park, Illinois ( PRN/ots ) - - HUMIRA Data Shows Slowed Joint Damage in Pivotal Study Abbott ( NYSE: ABT ) announced it has simultaneously submitted a Type II Variation to the European Medicines Agency ( EMEA ) and a supplemental Biologics License Application ( sBLA ) with the (...) - - Sixty - two percent of the patients achieved ACR50, one of the study's primary endpoints, at one year. ACR50 is a measure used by the American College of Rheumatology indicating 50 percent or greater improvement in symptoms, including pain, number of swollen joints and physical function. - - Sixty - one percent of the patients experienced inhibition of radiographic progression, as measured by total Sharp score ( TSS ) - a secondary endpoint of the study. TSS assesses bone erosion and joint - space narrowing on X - rays. - - One out of every two patients achieved remission as defined by DAS 28<2.6. DAS 28 ( Disease Activity Score 28 ) measures disease activity responses for RA by assessing tender and swollen joint count, general health status and an inflammatory marker in the blood. "In as little as one year, RA can cause measurable joint damage in patients taking traditional DMARDs such as methotrexate," said Alejandro Aruffo, Ph.D., president, Abbott Bioresearch Center and Immunoscience Development Center, Abbott. "While HUMIRA has already provided benefit to more than 83,000 patients worldwide, we are hopeful that once approved as a first - line treatment it could help many more. We are continually investigating new uses for HUMIRA and other treatments and compounds, in keeping with Abbott's commitment to develop innovative medicines and to address major unmet medical needs." PREMIER, a two - year, double - blind, controlled study, compared the effectiveness of HUMIRA, MTX and the two drugs combined in treating early RA. Also, it was the first trial of a TNF antagonist ( a treatment that targets TNF, a protein implicated in RA ) to set ACR50 as a primary endpoint and achieve it. Researchers compared ACR50 responses ( a measure used by the American College of Rheumatology indicating 50 percent or greater improvement in symptoms, including pain, number of swollen and tender joints and physical function ) and radiographic progression in 799 adult patients with recent - onset RA who had not previously used MTX. Patients, separated into three groups, received either HUMIRA ( 40 mg every other week subcutaneously ) combined with MTX ( rapidly escalated to 20 mg weekly ); MTX alone; or HUMIRA alone. Results showed that HUMIRA in combination with MTX significantly improved signs and symptoms of early RA patients. Sixty - two percent of patients receiving the combination therapy achieved the primary endpoint of ACR50 at one year, compared to only 46 percent in the MTX - only group. In addition, after two years, one out of every two patients with early RA who received a combination of HUMIRA and methotrexate achieved clinical remission ( as defined by DAS 28<2.6 ) compared to only 25 percent of patients receiving methotrexate alone. DAS 28 ( Disease Activity Score 28 ) measures disease activity responses for RA by assessing tender and swollen joint count, general health status and an inflammatory marker in the blood. PREMIER's secondary endpoint, inhibition of radiographic progression, was measured by the change in total Sharp score ( TSS ). The HUMIRA - MTX combination was significantly more effective at inhibiting radiographic progression with nearly twice as many patients ( 61 percent ) experiencing disease inhibition compared to patients who exhibited disease inhibition with MTX only ( 34 percent ). After two years, patients in the MTX - only group experienced five times the radiographic progression of patients in the HUMIRA - MTX combination group, with TSS increases averaging 10.4 and 1.9, respectively. The differences between the combination group and the MTX group were statistically significant ( p<0.001 ). "Early and aggressive treatment can help slow the progression of joint deformity and disability caused by rheumatoid arthritis," said Ferdinand Breedveld, M.D., Leiden University Medical Center, Leiden, the Netherlands and an investigator for the PREMIER trial. "Studies have shown that people who receive early treatment for RA are less likely to experience the type of joint damage that leads to joint replacement." About RA More than 5 million people worldwide suffer from RA, a chronic autoimmune disease that causes pain, swelling and stiffness in the joints of the hands, feet and wrists, and often leads to the destruction of joints. Unlike osteoarthritis, the most common form of arthritis, RA is an autoimmune disease where joints are inflamed, resulting in eventual destruction of the joints' interior and the surrounding bone. More information on RA and current treatment options can be found at http://www.RA.com . Important Safety Information Common adverse events ( >1/100 and less than or equal to 1/10 ) at least possibly causally related to HUMIRA include headache, dizziness, respiratory tract and urinary tract infection, nausea, diarrhea, sore throat, herpes simplex, abdominal pain, rash, pruritis and anemia. Injection site pain was reported by >1/10 patients. Patients must be monitored closely for infections, including tuberculosis ( TB ), before, during and after treatment with HUMIRA. Treatment should not be initiated in patients with active infections until infections are controlled. Patients who develop new infections while using HUMIRA should be monitored closely. HUMIRA should not be used by patients with active TB or other severe infections such as sepsis and opportunistic infections. HUMIRA should be discontinued if a patient develops a new serious infection until infections are controlled. Physicians should exercise caution when considering use of HUMIRA in patients with a history of recurring infection or with underlying conditions that may predispose patients to infections. TNF - antagonists, including HUMIRA, have been associated in rare cases with exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Prescribers should exercise caution in considering the use of HUMIRA in patients with pre - existing or recent - onset central nervous system demyelinating disorders. HUMIRA should be used with caution in patients with mild heart failure, and is contraindicated in patients with moderate or severe heart failure. HUMIRA must be discontinued in patients who develop new or worsening symptoms of congestive heart failure. About HUMIRA HUMIRA is the only fully human monoclonal antibody approved by the FDA and EMEA for reducing the signs and symptoms, inhibiting the progression of structural damage and improving physical function in adults with moderately to severely active RA who have had insufficient response to one or more DMARDs. HUMIRA can be used alone or in combination with methotrexate or other DMARDs. HUMIRA offers convenient every - other - week dosing by subcutaneous injection ( shot beneath the skin ) via a specially designed, pre - filled syringe. Clinical trials are currently underway evaluating the potential of HUMIRA in other autoimmune diseases, including juvenile rheumatoid arthritis ( JRA ), psoriasis, psoriatic arthritis, Crohn's disease and ankylosing spondylitis. In addition to filing for HUMIRA as a treatment for early RA, Abbott also filed an sBLA in the U.S. and a Marketing Authorization Application ( MAA ) in the E.U. for HUMIRA for the treatment of psoriatic arthritis. About Abbott Abbott is a global, broad - based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 55,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com . Web site: http://www.abbott.com ots Originaltext: Abbott Im Internet recherchierbar: http://www.presseportal.de Contact: International Media, Rand Walton, +1 - 847 - 938 - 8848, or U.S. Media, Jim Bozikis, +1 - 847 - 937 - 6844, or Financial Community, Larry Peepo, +1 - 847 - 935 - 6722, all of Abbott Company News On - Call: http://www.prnewswire.com/comp/110328.html
2006-05-21:
Two Thirds of Family Doctors Believe COPD will be the Leading Cause of Death in 2020
San Diego, California ( PRN/ots ) - - For Accredited International Healthcare Journalists Only - Management of Exacerbations `Crucial' to Reduce COPD Mortality Survey results from the `Time to Live' report, presented today at the American Thoracic Society International Congress, show over two thirds of (...)
2008-11-09:
CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
New Orleans, November 9 ( PRN/ots ) - New data from the JUPITER study demonstrated that CRESTOR( R ) ( rosuvastatin calcium ) 20 mg significantly reduced major cardiovascular ( CV ) events ( defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death (...)
2007-10-11:
Micropill Belara® improves impure skin
Paris ( na Originaltextservice ) - At this year's 7th congress of the European Society of Gynaecology ( Paris, 10 - 14 October 2007 ), the German pharmaceutical company Grunenthal GmbH presents the latest study results for its oral contraceptive Belara®. As the first of its kind the (...)
2011-04-11:
European Survey Reveals Wide - Reaching Impact of eczema on Quality of Life and Emotional Wellbeing of Children and Their Families
London ( PRN/ots ) - New survey data released today demonstrate that childhood eczema can have a detrimental effect on quality of life not only for the children who live with the disease, but also for their families.[1a] The survey, which was carried out (...)
2006-07-18:
Novartis to Build Latest - Technology Influenza Vaccines Manufacturing Site in North Carolina
Basel, Switzerland ( PRN/ots ) - - Novartis Vaccines on track to be the first to manufacture new cell culture - derived influenza vaccines in the United States - New site to support pandemic preparedness - First submission of a cell culture - derived influenza vaccine (...)
2010-01-21:
New Real World Avastin Data From Over 3,200 Metastatic Colorectal Cancer Patients Confirms Survival Benefit Beyond 2 Years
Basel, Switzerland ( PRN/ots ) - New data from two large studies observing the routine use of Avastin - based therapy in more than 3,200 patients will be announced showing impressive treatment benefits in a non - selected patient population. Key findings included high rates of tumour shrinkage (...)
2008-05-29:
Wyeth Receives FDA Fast Track Designation for its 13 - valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
Collegeville, Pennsylvania ( PRN/ots ) - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation to the Company's investigational 13 - valent pneumococcal conjugate vaccine for infants and toddlers. Wyeth is seeking (...)
2008-11-13:
New Antibiotic Against Serious Infections - Receives First Approval in Europe
Baar, Switzerland, November 13 ( PRN/ots ) - - ZEVTERA( TM ) A Broad - spectrum, Anti - MRSA Cephalosporin Antibiotic to Treat Complicated Skin and Soft Tissue Infections Approved in Switzerland - Not for UK Media Swissmedic, the Swiss agency for therapeutic products, has approved ZEVTERA( TM ) ( ceftobiprole medocaril ) for (...)
2004-11-23:
Amino acids for animal feed: Complete Single - Source Service
Dusseldorf ( na Originaltextservice ) - - Cross - reference: photo was sent via satellite and is available at http://www.presseportal.de/galerie.html The world's population is continuing to grow, and it is moving into the cities at an ever - increasing pace. The United Nations forecast (...)
2006-09-07:
European Commission Expands Indication for PLAVIX( R ) ( clopidogrel bisulfate ) Offering New Option for Patients With Most Severe Type of Heart Attack
Paris ( PRN/ots ) - - PLAVIX indication expanded to include patients with any acute coronary syndromes ( ACS ) - Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) and Bristol - Myers Squibb Company ( NYSE: BMY ) announced today that the European Commission has granted a new indication for (...)
2008-02-04:
Promising Phase 3 Data for Ustekinumab ( CNTO 1275 ) in Long - Term Improvement of Chronic Plaque Psoriasis
San Antonio, Texas ( PRN/ots ) - - New Findings From a Second Pivotal Phase 3 Study Show Subjects Receiving Ustekinumab Every 12 weeks Maintained Improvement From Psoriasis Through One Year One - year data from the second double blind, placebo - controlled Phase 3 study PHOENIX (...)
2009-07-06:
European Commission Approves Statement on Lipid Improvement for VIRAMUNE( R ) Label
Ingelheim, Germany ( PRN/ots ) - - For Medical Media Outside the US only Boehringer Ingelheim announced today that the European Commission has approved an update of the Summary of Product Characteristics ( SmPC ) for VIRAMUNE( R ) ( nevirapine ) in the treatment of patients with HIV. The decision (...)
2009-06-30:
New Data Supports Significant Economic and Clinical Value of MENOPUR( R ) in IVF
Amsterdam, The Netherlands ( PRN/ots ) - - "Study Could Have Major Impact on the Decision - Making Process With Respect to Infertility Treatment" New data from an economic analysis presented today at this year's European Society of Human Reproduction and Embryology ( ESHRE ) congress showed that, (...)
2008-04-16:
European Regulatory Agency Grants Orphan Status to Morphotek( R )'s Farletuzumab and MORAb - 009
Exton, Pennsylvania ( PRN/ots ) - - Upon Marketing Authorization Orphan Status Would Provide for Ten Years of Market Exclusivity in the European Union for Both Investigational Treatments Morphotek( R ), Inc., a subsidiary of Eisai Corporation of North America, announced today that the European Commission has (...)
2007-04-30:
Advagraf( R ) Now Approved Across Europe as a Once - Daily Immunosuppressant in Organ Transplantation
London ( PRN/ots ) - Astellas announced today that the European Commission has approved the immunosuppressant Advagraf( R ) ( generic name: tacrolimus, prolonged release ) for prophylaxis of transplant rejection in adult kidney or liver allograft recipients and for the treatment of allograft rejection resistant to treatment with other immunosuppressive (...)
2005-05-02:
Hospira Launches in the Netherlands
Amsterdam, Netherlands ( PRN/ots ) - - Hospira Healthcare B.V. will also serve as regional headquarters for Europe, Middle East and Africa - - Today Hospira, Inc. ( pronounced Hos - PEER - ah ), a global independent specialty pharmaceutical and medication delivery company created in April 2004 from the (...)
2005-10-22:
Head to Head Study Confirms Atypical Antipsychotic Efficacy Equivalence
Amsterdam, The Netherlands ( PRN/ots ) - - New data also demonstrate SEROQUEL tolerability benefits versus other atypicals in schizophrenia and reinforce therapeutic potential in bipolar disorder Seroquel ( quetiapine ), olanzapine and risperidone are equally effective in patients experiencing first episode psychosis, according to data presented today (...)
2007-07-26:
MIRCERA Approved in European Union for Treatment of Anaemia Related to Chronic Kidney Disease
Basel, Switzerland ( PRN/ots ) - - First Anti - Anaemia Product Offering Simple Once - Monthly Maintenance Treatment Roche announced today that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease ( CKD ). The approval of MIRCERA results in (...)
2008-11-14:
SYGNIS Receives Orphan Drug Designation from the European Commission for AX200 in the treatment of Spinal Cord Injury
Heidelberg ( na Originaltextservice ) - - Second indication for AX200 given Orphan Drug status SYGNIS Pharma AG ( Frankfurt: LIO; ISIN DE0005043509; Prime Standard ), today announced that it has received Orphan Drug designation from the European Commission for AX200 in the treatment of Spinal (...)
2005-10-17:
New Data Confirm Pramipexole Delivers Sustained Efficacy For Patients With Restless Legs Syndrome
Berlin, Germany ( PRN/ots ) - - For Healthcare Professional Journalists - Not for distribution to US media - Randomised, Placebo - Controlled Study Shows Discontinuation of Pramipexole Leads to Rapid Worsening of Symptoms - Two new, randomised, placebo - controlled studies presented this week at the inaugural conference (...)
2007-01-10:
SemBioSys' Plant - Produced Insulin Chemically and Physiologically Equivalent to Commercial Insulin in Animal Studies
Calgary, Alberta ( PRN/ots ) - - Canadian Biotechnology Company Takes Next Significant Step Towards Advancing its Product to the Clinic - SemBioSys Genetics Inc. ( TSX:SBS ), a biotechnology company developing a broad pipeline of protein - based pharmaceuticals and non - pharmaceutical products, today announced that (...)
2009-02-07:
Nplate( R ) Approved in the European Union for the Treatment of Chronic Immune ( Idiopathic ) Thrombocytopenic Purpura ( ITP )
Zug, Switzerland ( PRN/ots ) - - First and Only Approved Platelet Producer in Europe Represents New Treatment Approach for Serious Chronic Autoimmune Disorder Amgen ( Nasdaq: AMGN ) today announced that the European Commission ( EC ) has granted marketing authorisation for Nplate( R ) ( romiplostim ) for the treatment of (...)
2006-07-24:
MedifyRemote Live Date Confirmed
Gateshead, England ( PRN/ots ) - Medify Solutions Limited ( Pink Sheets: MFYS ) confirms the scheduled go - live date for MedifyRemote to its NHS customers is 1st September 2006. Executive Chairman Jonathan Bryant said, "The confirmation of the go live date for MedifyRemote is an announcement we (...)
2008-06-18:
Key Primary Resverlogix Objective Obtained
San Diego, California and Calgary, Canada ( PRN/ots ) - - Findings Demonstrate Clear Trends of Proof of Principle of Reverse Cholesterol Transport in Human Volunteers SAN DIEGO, California and CALGARY, Canada, June 18 /PRNewswire/ - - Resverlogix Corp. ( "Resverlogix" or the "Company" ) ( TSX: RVX ) announced (...)

back... 1 2 3 4 5 6 7 8 9 10 11 more...



» German Health-Sites

Medical and health related Websites from Germany

Alternative Medicine
Beauty and Wellness
Manufacturers of Medical Equipment
Biotechnology
International
Databases
German Doctors Worldwide
German Medicine and Patient Transfer
Special Diagnoses
Acne
Cancer
Diabetes
Nutrition and Diet
Family
Fitness and Sports
Forums
Womens Health
Genetics
Health-Marketing
Dating
Health Insurance
Other Insurances
Literature and Publishers
Newspaper / Magazines
Organizations
Care
Portals and Directories
Pharmacies
Portals and Directories Dental Medicine
Search
Psyche
Public Health
Governmental Links
Guides
Regional
Baden-Wuerttemberg
Bavaria
Berlin
North Rhine-Westphalia
Travel Medicine
Self-Help
AIDS
Alcoholism
Alzheimer
Medical malpractice
Visually Impaired
Seminar
Seniors / 50+
Seniors / Living
Shopping
Medical Technology
Children-, Youth- and Social Work
Scholastics
Accommodation
Organization
Mixed


© 2003-2008 med-kolleg.de Health Provider Directory
Clinics and Physicians
Berlin, Germany Dienstag, 22.10.2019.
Sitemap (Sitemap German) Imprint Press (German)
Ärzteverzeichnis Klinikverzeichnis Apothekenverzeichnis Ärztesuche
 Sun, 20 Oct 2019 10:24:13 GMT
Werben im Gesundheitssektor / Medizin

Health Provider Directory

Medizin und Gesundheit - Arztsuche Kliniksuche Apothekensuche
Gesundheitsportal